PAS
BCRX icon

Park Avenue Securities’s BioCryst Pharmaceuticals BCRX Stock Holding History

Park Avenue Securities’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-40,097
Closed -$424K – 1115
2022
Q2 		$424K Hold
40,097
– – 0.01% 764
2022
Q1 		$652K Sell
40,097
-9,903
-20% -$159K 0.01% 628
2021
Q4 		$693K Hold
50,000
– – 0.01% 588
2021
Q3 		$719K Buy
+50,000
New +$789K 0.01% 523

Other funds holding BCRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Park Avenue Securities's BCRX Position: Q3 2022 in Review

Park Avenue Securities sold out of BioCryst Pharmaceuticals (BCRX) in Q3 2022, closing a stake of 40,097 shares — an estimated $424K sold.

Park Avenue Securities first reported a position in BCRX in Q3 2021 and held it in 4 quarters. The position peaked at $719K in Q3 2021. 234 funds tracked by Wall St. Rank hold BCRX as of Q3 2022.

  • Park Avenue Securities reported no remaining BioCryst Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Park Avenue Securities sold 40,097 BioCryst Pharmaceuticals shares in Q3 2022, an estimated $424K.
  • Park Avenue Securities first reported a position in BioCryst Pharmaceuticals in Q3 2021 and held it in 4 quarters.
  • Park Avenue Securities's BioCryst Pharmaceuticals position peaked at $719K in Q3 2021.
  • 234 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q3 2022.

Based on Park Avenue Securities's 13F filing for Q3 2022, filed 1 Nov 2022.